TMCnet News

Research and Markets: Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015
[September 10, 2015]

Research and Markets: Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015


Research and Markets (http://www.researchandmarkets.com/research/tzkczb/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC (News - Alert) filings, investo presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.



The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned


Partial List of the 70+ companies mentioned in this comprehensive report:

  1. Absynth Biologics
  2. Bharat Biotech International
  3. C3 (News - Alert) Jian
  4. Debiopharm International
  5. Ensoltek
  6. Galapagos
  7. Helix BioMedix
  8. Ildong Pharmaceutical
  9. Kyorin Pharmaceutical
  10. LegoChem Biosciences
  11. Madam Therapeutics
  12. Nabriva Therapeutics
  13. Oragenics
  14. Pepscan Presto
  15. Redx Pharma
  16. Sarepta Therapeutics
  17. Savara
  18. Sealife PHARMA
  19. Sentinella Pharmaceuticals
  20. Soligenix
  21. Sorrento Therapeutics
  22. Syntiron
  23. Taejoon Pharm
  24. TAXIS Pharmaceuticals
  25. Tetraphase Pharmaceuticals
  26. United Therapeutics
  27. Wintermute Biomedical
  28. Wockhardt
  29. XBiotech USA
  30. Yungjin Pharm

For more information visit http://www.researchandmarkets.com/research/tzkczb/methicillinresist


[ Back To TMCnet.com's Homepage ]